Zobrazeno 1 - 7
of 7
pro vyhledávání: '"L S, Grauer"'
Publikováno v:
The Prostate. 43(2)
Prostate-specific membrane antigen (PSMA) is a 750-residue integral membrane glycoprotein and the target of an in-vivo imaging agent for metastatic prostate carcinoma (PCa). PSMA expression in normal and diseased prostatic tissues has previously been
Publikováno v:
Cancer. 88(2)
Prostate specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed in benign prostate secretory-acinar epithelium and prostate carcinoma. The results of several studies suggest that PSMA expression is increased in prostate car
Publikováno v:
Cancer research. 59(13)
Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that was initially characterized by the monoclonal antibody (mAb) 7E11. PSMA is highly expressed in prostate secretory-acinar epithelium and prostate cancer as well
Publikováno v:
Cancer research. 58(21)
An alternatively spliced variant of prostate-specific membrane antigen (PSMA) designated PSM' was originally described following identification of its mRNA in normal prostate. We have purified the PSM' protein from LNCaP cells using two immunoaffinit
Publikováno v:
Journal of andrology. 19(4)
Forms of human glandular kallikrein (kK2) in prostate carcinoma serum were identified using monoclonal antibodies specific for hK2 and prohK2. Recombinant mammalian hK2, prohK2, and prostate = specific antigen (PSA) were utilized to confirm the speci
Autor:
L S, Grauer, M C, Charlesworth, M S, Saedi, J A, Finlay, R S, Liu, K, Kuus-Reichel, C Y, Young, D J, Tindall
Publikováno v:
Journal of andrology. 17(4)
Based on studies indicating that human glandular kallikrein (hK2) mRNA is present in the prostate, we prepared a monoclonal antibody to a synthetic peptide corresponding to the 41-56 region of hK2 to try to identify the hK2 protein. Although prostate
While monoclonal antibodies show promise for use in the treatment of a variety of disease states, including cancer, autoimmune disease, and allograft rejection, generation of anti-antibody responses still remains a problem. For example, 50% of the pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b1af1ac839d3f6b8783e2fef4f834c
https://europepmc.org/articles/PMC368269/
https://europepmc.org/articles/PMC368269/